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Abstract Telaprevir (LY 570310; LY-570310; LY570310;MP 424; MP-424; VX 950;
VX-950) is an orally administered peptidomimetic inhibitor of the hepatitis C
virus (HCV) protease NS3/4A. It is being developed by Vertex Pharmaceu-
ticals and its licensees for the treatment of HCV infections and has recently
been submitted to the US FDA for approval. As the first ever HCV protease
inhibitor in phase III development, it is being studied in trials in combination
therapy with pegylated interferon alfa-2a and ribavirin in Europe, the US,
Australia, Canada, and Puerto Rico in treatment-naive and treatment-
experienced patients with HCV genotype 1 infection. Phase III trials of telap-
revir as combination therapy are also in progress in Japan. This review
discusses the key developmentmilestones and therapeutic trials of this drug todate.
1. Introduction
Telaprevir is an orally administered peptido-
mimetic inhibitor of the hepatitis C virus (HCV)
protease NS3/4A. It is being developed by Vertex
Pharmaceuticals and its licensees, Janssen Phar-
maceutica, Tibotec, as well as Mitsubishi Tanabe
Pharma Corporation (formerly Mitsubishi Pharma
Corporation), for the treatment of HCV infec-
tions. A rolling new drug application (NDA)
submission is underway in the US in this indica-
tion. Telaprevir is the first ever HCV protease
inhibitor to begin phase III development. The
agent is being studied in phase III trials as part of
combination therapy with pegylated interferon
(peg-IFN) alfa-2a and ribavirin (RBV) in Europe,
the US, Australia, Canada, and Puerto Rico in
treatment-naive and treatment-experienced patients
withHCV genotype 1 infection, themost difficult-
to-treat variant of the disease. Phase III trials of
telaprevir as combination therapy are also in pro-
gress in Japan. A phase II study of telaprevir in
combination with the HCV NS5B polymerase
inhibitor VX 222 is in progress in the US. Phase II
development of telaprevir as a monotherapy is
also ongoing in various countries.
NS3/4A protease activity is essential for viral
replication and is partially responsible for the
ability of HCV to evade clearance by the immune
system of the host. Therefore, protease inhibition
could offer a double hit strategy against HCV.
1.1 Company Agreements
In June 2006, Vertex entered into a license,
development, manufacturing, and commerciali-
zation agreement with Janssen Pharmaceutica
(a subsidiary of Johnson & Johnson). Under the
collaboration agreement, Vertex will collaborate
with Janssen to develop and commercialize tela-
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previr. Under the terms of the collaboration
agreement, Vertex will retain exclusive commercial
rights to telaprevir in North America (the US,
Canada, and Mexico) and will continue to lead
the development plan for telaprevir in North
America and the Janssen territories. Janssen re-
ceived exclusive rights to commercialize telaprevir
outside of North America and the Far East. An-
other subsidiary of Johnson & Johnson, Tibotec,
will lead the development and commercialization
of telaprevir for Janssen. However, Vertex will
continue to lead the global development plan for
telaprevir. Each company will be responsible for
the supply of telaprevir in their respective territories.
Tibotec has the exclusive rights to telaprevir in
Europe, South America, Middle East, Africa,
India, Australia, andNew Zealand.[1-4] Under the
agreement, Janssen agreed to pay Vertex a total
of $US250 million in aggregate milestone pay-
ments for the development and launch of tela-
previr in the EU. Vertex announced in July 2009
that it intends to sell its rights to these milestone
payments.[5] Later, in September 2009, Vertex
announced that it will receive $US155 million
cash related to future telaprevir milestone pay-
ments. Of this $US155 million, approximately
$US120 million is for the issuance of notes re-
payable no later than October 2012; the remaining
$US35 million is for the sale of rights to potential
future milestones tied only to the European
launch of telaprevir, which Vertex is eligible to
receive from Janssen.[6]
In June 2004, Vertex and Mitsubishi Pharma
Corporation (Mitsubishi Tanabe Pharma Corpo-
ration since October 2007) entered into an agree-
ment providing the latter with exclusive rights to
develop and commercialize telaprevir in Japan
and certain Far East countries. Under this agree-
ment,Mitsubishi Tanabe was required to pay royal-
ties to Vertex on commercial sales of telaprevir in
its territories. The agreement provided certain de-
velopment and commercial rights to telaprevir as
a monotherapy agent for the treatment of hep-
atitis C. In July 2009, the agreement was amend-
ed. This amendment grants Mitsubishi a licence
to commercialize telaprevir as part of a combina-
tion regimen with IFN and RBV to treat hepatitis
C in Japan and the Far East. Vertex retains ex-
clusive development and commercial rights to
telaprevir in North America.[7-9]
In November 2003, Vertex entered into a non-
exclusive licensing agreement with Chiron Corpo-
ration (now Novartis), granting Vertex a license
to discover, develop, and commercialize small-
molecule therapeutic agents against certain hep-
atitis C drug targets. In return, Chiron received
limited rights to review telaprevir for potential
licensing. The agreement may provide Chiron with
certain developmental milestone payments and
royalty payments based on future sales of telaprevir,
if approved. Chiron was subsequently acquired
by, and merged into, Novartis in April 2006.[10]
Telaprevir originated from a research collab-
oration between Vertex and Eli Lilly. The agree-
ment was restructured in 2003 such that Vertex
obtained the worldwide rights to compounds
identified during the collaboration and Eli Lilly
retained a financial interest in telaprevir and
other HCV protease compounds through royal-
ties on net product sales.[11]
In February 2009, Vertex secured $US320
million in a stock offering.[12] The funds will be used
partly to advance the development of telaprevir.
1.2 Key Development Milestones
In mid-2010, Vertex submitted the non-clinical
and the chemistry, manufacturing, and controls
sections of its rolling NDA to the US FDA, for
telaprevir in the treatment of HCV infections.
The company expects to complete the NDA
submission by the end of 2010.[13]
Telaprevir has been evaluated in three pivotal
phase III trials that included more than 2200
patients in the US and Europe. Two of the trials
(ADVANCE [A New Direction in HCV Care: A
Study of Treatment-Naive Hepatitis C Patients
with telaprevir] and ILLUMINATE) were stud-
ies in treatment-naive patients, whereas the third
trial (REALIZE [Re-treatment of Patients with
Telaprevir-based Regimen to Optimize Outcomes])
is a study in patients who have failed previous
therapy. Sustained viral response (SVR) data
have been reported for the ADVANCE and
ILLUMINATE studies, and efficacy and safety
data for REALIZE are expected to be available
180 Adis R&D Profile
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (3)
in September 2010. These results will support
NDA and MAA submissions in the US and
Europe, respectively.[5,13,14] In December 2005, the
FDA granted fast-track designation to telaprevir
for the treatment of HCV infections.[15] In Japan,
telaprevir is also in phase II development as a
monotherapy.
1.2.1 Treatment-Naive Patients with Hepatitis C Virus
(HCV)
In the fourth quarter of 2010, Vertex and Tibo-
tec plan to initiate a phase IIIb trial to evaluate
twice-daily telaprevir (1125mg) compared with
three-times-daily telaprevir (750mg, every 8 hours).
The trial will enroll 700 patients in the US, the
EU, and other countries. Based on advice from
regulatory authorities in the US and the EU, the
trial will not include a control arm of peg-IFN
and RBV.[13]
Vertex and Tibotec have reported SVR data
from the pivotal, phase III, ADVANCE Study
(NCT00627926), which is being conducted at sites
in the US, EU, and certain other countries. This
study has completed enrollment of 1050 treatment-
naive patients with HCV genotype 1 infections,
and will evaluate two 24-week telaprevir-based
regimens (in combination with standard doses of
peg-IFN alfa-2a and RBV) in comparison with a
48-week control arm (peg-IFN +RBV alone).
The primary endpoint of the study is SVR (de-
fined as undetectable HCV RNA [<10 IU/mL])
24 weeks after completion of treatment; interim
results showed that 75% of patients treated with
telaprevir for 12 weeks achieved SVR. All patients
in the ADVANCE trial have completed dosing of
all study drugs.[16-21]
A phase III trial, ILLUMINATE, of telaprevir-
based treatment for 24 weeks, or extended treatment
to 48 weeks, in patients with chronic hepatitis C
began in September 2008 (NCT00758043; VX08-
950-111). Approximately 500 patients were recruited
at sites in the US, Belgium, the Netherlands, and
Puerto Rico. Telaprevir was administered as
750mg three times daily for 12 weeks, in combi-
nation with RBV (1000–1200mg/day) and peg-
IFN (180 mg/week) for either 24 or 48 weeks. The
aim of the study was to determine the relative
benefits of 24 or 48 weeks of total treatment in
patients that respond quickly to a telaprevir-
based treatment. Results were released in August
2010.[17,22]
In March 2010, Vertex initiated a phase II
combination trial of telaprevir and VX 222 in
treatment-naive patients with HCV genotype 1
infection. The primary endpoint of the random-
ized, dose-ranging trial is to assess the safety and
tolerability of the combination therapy. The trial
will also evaluate SVR rates as a secondary end-
point. Approximately 100 patients will be enrolled
at 20 clinical trial sites, mainly in the US, and
treatment duration will be 12 weeks. All patients
will receive telaprevir 1125mg twice daily; VX 222
will be administered as 100mg or 400mg twice
daily. Some patients will receive follow-on ther-
apy with peg-IFN and RBV.[17,23] On-treatment
data from this trial are expected in the second half
of 2010.[13,24]
In October 2009, Vertex and Tibotec initi-
ated a phase IIa study in patients with HIV/HCV
co-infection.[25] The two-part, randomized, double-
blind, placebo-controlled, parallel-group, multi-
center study (NCT00983853)will evaluate telaprevir
in combination with peg-IFN alfa-2a (Pegasys)
and RBV (Copegus) in treatment-naive patients
with chronic HCVwho are co-infected with HIV-
1 infection. Patients are being recruited in the US,
France, and Germany. Study completion is ex-
pected in June 2012.
Tibotec has completed a phase II trial (VX-
950-TiDP24-C208; NCT00528528) of twice-daily
versus three-times-daily dosing of telaprevir.
The trial was initiated at sites in Belgium and
Germany with the intention to include additional
sites in France, Italy, the Netherlands, and Spain.
Enrollment of 161 treatment-naive patients with
chronic HCV genotype 1 infection has been
completed. Patients are receiving either telaprevir
(1125mg every 12 hours) or telaprevir (750mg
every 8 hours) for 12 weeks in combination with
standard therapy. Interim results reported in July
2008 and final data presented in October 2009
showed that more than 80% of patients had un-
detectable HCV RNA at weeks 4 and 12 in both
dosing arms, with no substantial differences in
safety observed between the two dosing regi-
mens.[4,26-29]
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A phase II viral kinetics study of telaprevir
(VX-950-TiDP24-C209; NCT00561015) was
completed in Europe by Tibotec in the first half
of 2009. This trial recruited treatment-naive
patients with HCV genotype 2/3 infections.[29]
Vertex initiated a 28-day phase II trial of tela-
previr in combination with peg-IFN and RBV
in 12 treatment-naive patients with HCV infec-
tion inDecember 2005. Positive preliminary results
have been reported. This study was not designed
to evaluate SVRs in telaprevir recipients.[30,31]
1.2.2 Treatment-Experienced Patients with HCV
Tibotec is conducting the pivotal phase III
REALIZE trial (VX-950-TiDP24-C216; NCT-
00703118) to assess the efficacy, safety, and toler-
ability of telaprevir in combination with peg-IFN
alfa-2a andRBV in patients who have failed prior
standard of care treatment (peg-IFN alfa-2a plus
RBV). The REALIZE trial has enrolled approx-
imately 650 patients with HCV genotype 1 infec-
tions and is being conducted inAustralia, Canada,
Puerto Rico, the EU, and the US. The trial is de-
signed to evaluate two 48-week telaprevir-based
regimens in comparison with a 48-week control
arm (standard doses of peg-IFN and RBV). Te-
laprevir will be dosed for 12 weeks; the pri-
mary endpoint of the trial is SVR.[25,32,33] All
patients in the REALIZE trial have completed
dosing of all study drugs. A phase III roll-over
trial (NCT01054573) providing telaprevir to pa-
tients from the control group in this study who
failed treatment for virologic reasons began en-
rollment in March 2010.
An observational, follow-up study began in
mid-2009 in patients with hepatitis C who had pre-
viously been treatedwith telaprevir (NCT00916474).
The expected completion date is mid-2013.
A non-blind, rollover, phase II trial of telap-
revir plus standard therapy (RBV plus peg-IFN
alfa-2a) has been conducted in the US, Canada,
and the EU in patients who participated in the
control arms of studies VX06-950-106, VX05-950-
104, and VX05-950-104EU and did not respond
to therapy; this study is identified as VX06-950-
107 (Study 107; NCT00535847; n = 170).[34,35] The
study has been completed, and results have been
reported.[36-38]
1.2.3 PROVE Trials
Vertex has completed the PROVE 3 (Inves-
tigation of HCV PROtease Inhibition for Viral
Eradication 3) phase IIb trial in the US, Canada,
Germany, the Netherlands, and Puerto Rico
(NCT00420784; VX06-950-106). This trial includ-
ed 453 patients with HCV genotype 1 who had
responded poorly to previous treatment. Final
results from PROVE 3 were positive, demon-
strating that adding telaprevir to the patient’s
treatment regimen resulted in cure of approx-
imately 50% of this difficult-to-treat population
whose therapy had failed and for whom no other
options currently exist.[39-42] PROVE 3 was initi-
ated in January 2007 and completed in April 2009.
In December 2006, Vertex announced interim
safety and antiviral analyses of PROVE 1 (Study
104; NCT00336479), a phase II US trial of tela-
previr in 260 treatment-naive patients with
genotype 1 infection. This generated a milestone
payment of $US15 million to Vertex from Jans-
sen. The second phase II trial in this program,
PROVE 2 (Study 104EU; NCT00372385), was
initiated in June 2006 in Europe and was com-
pleted in 2008. Preliminary results from PROVE
2 were consistent with the findings from PROVE
1. The PROVE 1 and PROVE 2 trials evaluated
the SVR rates, optimal treatment duration, and
the role of RBV in telaprevir-based therapy.[43,44]
Final results from the PROVE 1 and PROVE 2
trials have been reported.[14,18,45-48]
1.2.4 Development in Japan
In October 2008, Mitsubishi Tanabe initiated
phase III registration trials of telaprevir in Japan.
These trials will evaluate 12 weeks’ treatment with
telaprevir in combination with peg-IFN alfa-2a
plus RBV in both treatment-naive patients with
HCV genotype 1 infection (NCT00780416) and
in treatment-experienced patients (NCT00781274,
NCT00780910). All three trials have complet-
ed enrollment. Other clinical trials of telaprevir
have been initiated in Japan by Mitsubishi
Tanabe Pharma Corporation (a phase I trial,
NCT00591214, and a phase II trial, NCT00621296)
to assess the safety and efficacy of telaprevir
monotherapy in treatment-naive patients with
chronic genotype 1b hepatitis C.[7]
182 Adis R&D Profile
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (3)
1.2.5 Miscellaneous Studies
Other phase I studies have been completed that
assessed the effects of severe renal impairment
(NCT00903773), and co-administration of ciclo-
sporin and tacrolimus (NCT01038167), in subjects
treated with telaprevir. Another phase I study
(VX-950-TiDP24-C136; NCT00973388) has also
been completed to assess the effect of telaprevir
on electrocardiogram results in healthy volunteers.
1.3 Patent Information
Vertex has received a US patent (No. 6 117
639) for the technology to screen compounds for
activity against HCV protease, using a cell-based
assay. The invention is a proprietary tool that can
be used to accelerate the discovery of HCV pro-
tease inhibitors for the treatment of HCV in-
fection, and is also broadly applicable for drug




Telaprevir (750mg every 8 hours or 1125mg
every 12 hours) plus peg-IFN alfa-2 plus RBV
and telaprevir (750mg every 8 hours or 1125mg
every 12 hours) plus peg-IFN alfa-2 plus RBV
were associated with similar total telaprevir ex-
posure levels (measured as area under the con-
centration-time curve over 24 hours [AUC24])
according to a pharmacokinetic/pharmacodynamic
analysis of data from a randomized, open-label,
phase IIa trial (NCT00528528, C208) in 161
treatment-naive patients with chronic genotype 1
hepatitis C.[26]
Single-dose telaprevir was orally bioavailable
and achieved desired blood concentrations at
and above the middle range of the doses tested
(25–1250mg) among healthy volunteers in phase
Ia study. Blood concentrations of telaprevir ex-
ceeded the concentrations known to demonstrate
antiviral activity in preclinical studies. At certain
dose levels, these target concentrations were main-
tained for more than 12 hours. Analysis of com-
bined clinical and preclinical pharmacokinetic
results for telaprevir, based on its antiviral ac-
tivity in the replicon assay, indicated that average
liver concentration values were up to 57-fold
above the replicon 90% inhibitory concentration
and 113-fold above the 50% inhibitory concen-
tration.[49,50]
Results from a phase I study in 25 healthy male
volunteers showed that the apparent elimination
half-life (t½) value of telaprevir (25–1000mg)
Table I. Features and properties
Alternate names LY 570310; LY-570310; LY570310; MP 424; MP-424; VX 950; VX-950
Originator Eli Lilly
Highest development phase Preregistration (US)
Active development-indications Hepatitis C
Class Oligopeptides, small-molecules
Mechanism of action Hepatitis C virus NS3 protein inhibitors, hepatitis C virus NS4 protein inhibitors
Chemical name Cyclopenta(c)pyrrole-1-carboxamide, (2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-
N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydro-, (1S, 3aR, 6aS)-
Molecular formula C36 H53 N7 O6
CAS registry number 402957-28-2
Route of administration PO
Pharmacodynamics Inhibits HCV protease expressed in vivo; decreases steatosis induced by wild type HCV protease
Antimicrobial activity Exhibits antiviral activity in vitro; amino acid substitutions that confer resistance to telaprevir in HCV
genotype 1 also appear to confer improved fitness to the resistant variants
Drug interactions Increases exposure to tenofovir disoproxil fumarate by about 30%; increases plasma exposure to VX 222
ATC Codes
WHO ATC code J05A-E (protease inhibitors)
EphMRA ATC code J5B1 (viral hepatitis products)
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ranged from 2 to 6 hours in the ‡450mg dose
range and 1.5–3 hours in the 25–300mg dose
range.[51]
Results from a clinical study in 34 patients
with genotype 1 HCV infection showed that te-
laprevir (450–1250mg) accumulated to steady state
with a median accumulation index of 1.8. The
drug induced a biphasic HCV RNA decline, with
a rapid slope at day 1, followed by a second slower
slope. The average steady state trough concen-
tration was 781.1, 1054.6, and 675.5 ng/mL for
the 450, 750, and 1250mg doses, respectively.[52]
2.1.2 Animal Studies
Telaprevir has demonstrated good potency,
bioavailability, and pKa values. Telaprevir was




Phase II : There were no treatment dis-
continuations or serious adverse events (AEs)
reported in a phase II trial, according to prelim-
inary results.[54]
Phase I : Single oral dose administration of
telaprevir (25–1250mg) was well tolerated at all
dose levels and was not associated with any seri-
ous AEs among healthy volunteers in a phase Ia
study. In addition, there did not appear to be an
increase in AEs with increasing dose levels. No
dose-limiting toxicities were identified and a
maximum tolerated dose was not reached.[49,50]
Results from a phase I study in 25 healthy
male volunteers showed telaprevir (25–1000mg)
to be well tolerated with no serious or severe AEs
reported. Most AEs were mild and non-specific
in nature.[51]
In a double-blind, placebo-controlled, phase
Ib trial, telaprevir was well tolerated across three
different dose groups. No serious AEs were re-
ported and there were no treatment disconti-
nuations. In the trial 34 patients with chronic
genotype 1 HCV were randomized to receive te-
laprevir 450mg every 8 hours, 1250mg every 12
hours, or 750mg every 8 hours, or placebo for 14
days.[55,56] Prior to the phase Ib trial in patients
with HCV, Vertex completed dosing in 24 healthy
volunteers. No serious AEs or treatment dis-
continuations were reported, and the most com-
mon potentially drug-related AEs were headache
(5 of 24), diarrhea (3 of 24), frequent urination (2
of 24), sleepiness/drowsiness (2 of 24), and nausea
(2 of 24). Healthy volunteers were randomized to
the same treatment regimens as patients with
HCV.[57]
Final results from the phase I trial (known as
VX04-950-101) in 24 patients showed that telap-
revir was well tolerated after 5 days of multiple
dosing. All drug-related AEs were mild in severity.
No serious AEs were reported, and no subjects
discontinued treatment due to AEs.[58]
2.2.2 Combination Therapy Trials
Phase III : In the phase III ILLUMINATE
study, the most frequently reported AEs were
fatigue, pruritus, nausea, anemia, rash, and head-
ache, the majority of which were mild or moder-
ate in severity. ILLUMINATE compared the
effects of treatment continuation to either 24 or
48 weeks in approximately 500 previously treat-
ment-naive patients who achieved a virologic
response at 4 and 12 weeks of therapy with te-
laprevir in combination with peg-IFN and RBV.
The incidence of AEs leading to treatment with-
drawal was 6.9%, and more specifically, the rates
of withdrawal due to anaemia and rash were 1.1%
and 0.6%, respectively.[24]
The safety and tolerability profile of telaprevir
was consistent with that observed in previous
phase II trials, in the phase III ADVANCE trial
in patients with chronic, genotype 1 HCV infec-
tions. In this double-blind trial, patients were
randomized to one of two telaprevir arms (8 or
12 weeks therapy with telaprevir 750mg every
8 hours plus peg-IFN and RBV) or the control
arm (peg-IFN plus RBV for 48 weeks). After the
completion of the telaprevir treatment phase,
patients in the 12-week telaprevir arm received
either 12 or 36 weeks treatment with peg-IFN and
RBV alone, and patients in the 8-week arm re-
ceived either 16 or 40 weeks treatment with peg-
IFN and RBV alone; both based on response to
treatment at weeks 4 and 12. Compared with pre-
vious trials of the agent, an improvement in treat-
ment discontinuation rates due to AEs, including
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rash and anemia, was observed. The most com-
monAEs in the telaprevir arms were fatigue, rash,
pruritus, nausea, headache, and anemia; of which,
anemia, rash, pruritus, and nausea occurred more
frequently in the telaprevir arms than in the
control arm (peg-IFN plus RBV). The majority
of these AEs were mild to moderate in nature.
AEs leading to discontinuation of all study drugs
occurred in 6.9%, 7.7%, and 3.6% of patients
in the telaprevir 12-week, telaprevir 8-week and
control arms, respectively; discontinuations due
to anemia were observed in 0.8%, 3.3%, and 0.6%
of patients in each of the respective arms.[16]
Phase II : In a phase IIa trial, C209, the overall
incidence of AEs was similar across arms and the
most common AEs in the telaprevir arms were
skin-related events, nausea, influenza-like illness,
and asthenia in-line with previous reports. One
genotype 2 patient in T2/PR24 discontinued te-
laprevir due to rash. The trial enrolled subjects
with genotype 2/3 hepatitis C who were random-
ized to receive 15 days of telaprevir (750mg every
8 hours) followed by peg-IFN (180 mg/week) and
RBV (800mg/day) for 24 weeks (T2&PR24),
telaprevir and peg-IFN plus RBV followed by
22 weeks of peg-IFN plus RBV (TPR2&PR22),
or placebo/peg-IFN plus RBV followed by 22
weeks of peg-IFN plus RBV (Pbo/PR24).[59]
Data from a phase II trial (VX05-950-102) of
telaprevir in combination with peg-IFN alfa-2a
and RBV have shown that no serious AEs were
seen in patients with chronic genotype 1 HCV
infection who completed dosing. Telaprevir was
administered in a tablet formulation at a dose of
750mg every 8 hours for 28 days, in combination
with standard doses of peg-IFN alfa-2a andRBV.
The most common AEs observed in the study
were flu-like illness, fatigue, headache, nausea,
anemia, depression, itching, and rash. All of these
AEs were mild to moderate in severity, except for
one headache that was graded as severe. The AEs
reported were considered typical of peg-IFN alfa-
2a plus RBV treatment. The most common AEs
reported, including patients who did not receive
telaprevir, and regardless of possible relationship
to drug, have been headache, frequent urination,
gastrointestinal symptoms, myalgias (muscle pain
in AE table), skin disorders, and chills.[30,60]
The phase II, C208 study, evaluated a twice-daily
telaprevir dosing regimen versus a three-times daily
regimen; treatment-naive patients with genotype
1 HCV received telaprevir in combination with
RBV plus peg-IFN alfa-2a (Pegasys) or peg-
IFN alfa-2b (Pegintron). Four patients (10%) in
the three-times-daily peg-IFN alfa-2a and two
patients (5%) in the three-times-daily peg-IFN
alfa-2b arms discontinued due to AEs and one
patient (3%) and three patients (7%), respectively,
experienced virologic breakthrough. In the twice-
daily peg-IFN alfa-2a and twice-daily peg-IFN
alfa-2b arms, four patients (10%) and three pa-
tients (8%), respectively, discontinued due to AEs,
and two patients (5%) and three patients (8%),
respectively, experienced virologic breakthrough.[18]
According to the intent-to-treat (ITT) analysis
data from the study C208, the most frequently
reported AEs were pruritus, nausea, rash, anemia,
flu-like symptoms, fatigue, and headache. These
events were similar in patients receiving either
8-hourly or 12-hourly telaprevir-based regimens.
Five percent (8 of 161) of patients discontinued
treatment because of serious AEs, including rash
(3%, 4 of 161) and anemia (2%, 3 of 161).[26,27]
Data from a phase II rollover study (VX06-
950-107 or Study 107; NCT00535847) have shown
that ten of 117 patients (9%) discontinued all
therapy due to AEs, four due to rash and two to
anemia. Grade 3 rash and grade 3 anemia were
observed in 5% and 5% patients, respectively.
AEs reported in this study were similar to those
reported in prior phase II trials of telaprevir. The
most common AEs reported were rash (all types),
fatigue, pruritus, and headache. Study 107 was an
open-label study of patients who did not achieve
SVR after receiving peg-IFN and RBV in the
control arms of the phase II PROVE trials
(PROVE 1, PROVE 2, or PROVE 3) of telaprevir.
Patients in Study 107 were characterized as null
responders, partial responders, relapsers or break-
throughs, based on their antiviral response docu-
mented as a result of their participation in
the control arms of the PROVE trials. A total of
117 patients enrolled in Study 107, including
51 patients with prior treatment null response,
29 patients with prior treatment partial res-
ponse, eight patients with prior treatment viral
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breakthrough, and 29 patients with prior treat-
ment relapse. When Study 107 first began, all pa-
tients were to receive 12 weeks of telaprevir in
combination with peg-IFN plus RBV followed
by an additional 12 weeks of Peg-IFN plus RBV,
for a total of 24 weeks of therapy. In 2008, Study
107 was amended and underwent several changes,
most notably to the duration of treatment. Fol-
lowing these amendments, only patients who did
not achieve HCV RNA £100 IU/mL at week 4
were required to stop therapy. In addition, prior
treatment null responder patients were to receive
a 48-week telaprevir-based treatment regimen.
Patients with prior treatment relapse, prior treat-
ment viral breakthrough, and prior treatment
partial response were eligible to receive a response-
guided, 24-week telaprevir-based treatment regi-
men if they achieved undetectable HCV RNA at
week 4 and 12, otherwise these patients would
receive a 48-week regimen.[37,61] These results
were consistent with interim data from 94 of total
117 patients enrolled in Study 107.[38]
2.2.3 PROVE (Phase IIb) Trials
PROVE 1
Final data from the phase IIb, US-based
PROVE 1 trial have shown that treatment-naive
patients with chronic hepatitis C genotype 1 infec-
tion who received telaprevir in combination with
peg-IFN alfa-2a plus RBV, the most common
AEs were rash (37% with mild rash, 15% with
moderate rash, 7% with severe rash), pruritus,
nausea, and diarrhea. However, the proportion
of patients who discontinued treatment because
of an AE was higher in the three telaprevir-based
treatment arms (21%), compared with control
group (11%); this was predominantly due to the
incidence of drug-related rash. The median time
to treatment discontinuation because of rash in
the telaprevir groups was 73 days (range 8–88)
after the start of treatment. Serious AEs were
reported in 22 patients during treatment (4 con-
trol recipients and 18 telaprevir recipients); 15 of
these events were considered to be related to the
study drug. PROVE 1 was a phase IIb, random-
ized, double-blind, placebo-controlled trial that
enrolled and treated 250 treatment-naive patients
with HCV genotype 1 infection at 37 clinical trial
sites in the US. Patients received telaprevir
750mg (or placebo) orally every 8 hours, based
on treatment arm, and a once-weekly 180 mg in-
jection of peg-IFN alfa-2a, as well as a 1000mg or
1200mg weight-based daily oral dose of RBV.
PROVE 1 consisted of the following four treat-
ment arms: (i) a 24-week telaprevir-based arm
consisting of 12 weeks of telaprevir in combina-
tion with peg-IFN and RBV, followed by an ad-
ditional 12 weeks of peg-IFN and RBV alone;
(ii) a 48-week telaprevir-based arm consisting of
12 weeks of telaprevir in combination with peg-
IFN and RBV, followed by an additional 36 weeks
of peg-IFN and RBV alone; (iii) a 12-week
telaprevir-based arm consisting of 12 weeks of
telaprevir in combination with peg-IFN and RBV;
and (iv) a control arm consisting of 12 weeks of
placebo in combination with peg-IFN and RBV,
followed by 36 weeks of peg-IFN and RBV
alone.[14,46] These results were consistent with
earlier reported findings. After 12 weeks of treat-
ment, the percentage of patients who had dis-
continued treatment due to AEs was 11% of those
treated with telaprevir-based regimen versus 3%
of control patients. Serious AEs were noted in 3%
and 1% of patients in the telaprevir and control
groups, respectively.[43,62,63]
PROVE 2
Final results from the phase IIb, EU-based
PROVE 2 trial (n = 323) confirmed that treatment
with 24-week, telaprevir-based therapy was gen-
erally well tolerated in treatment-naive patients
with genotype 1 hepatitis C. The AE profile of the
drug was generally consistent with that seen in
the PROVE 1 trial. The most frequent AEs were
pruritus, headache, rash, fatigue, weakness (or
asthenia), and anemia. Additionally, 14% of pa-
tients receiving a 24-week telaprevir-based regi-
men discontinued all drugs due to AEs versus 7%
in the 48-week control arm. The discontinuation
rate due to severe rash (grade 3) for all treatment
in the telaprevir-based arms was approximately
7%. Although rash and pruritus were frequently
reported in this study, they did not always occur
in combination; both of these AEs regressed after
withdrawal of telaprevir and administration of
appropriate therapy. PROVE 2 was another
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phase IIb, randomized, partially double-blind,
placebo-controlled trial that enrolled and treated
323 treatment-naive patients with HCV genotype
1 infection at 28 clinical trial sites in France,
Germany, the UK, and Austria. As in PROVE 1,
patients in PROVE 2 received telaprevir 1250mg
as a single dose on day 1 and then 750mg (or
placebo) orally every 8 hours, based on treatment
arm, a once-weekly 180 mg injection of peg-IFN
alfa-2a, as well as a 1000mg or 1200mg weight-
based daily oral dose of RBV. PROVE 2 con-
sisted of the following four treatment arms: (i) a
24-week telaprevir-based arm consisting of 12
weeks of telaprevir in combination with peg-IFN
and RBV, followed by an additional 12 weeks of
peg-IFN and RBV alone; (ii) a 12-week telapre-
vir-based arm consisting of 12 weeks of telaprevir
in combination with peg-IFN and RBV; (iii) a 12-
week telaprevir-based arm consisting of 12 weeks
of telaprevir in combination with peg-IFN (no
RBV); and (iv) a control arm consisting of 12
weeks of placebo in combination with peg-IFN
and RBV, followed by 36 weeks of peg-IFN and
RBV alone.[14,18,47,48,64]
PROVE 1 and PROVE 2 Pooled Analysis
Two identical treatment regimen arms were
pooled: 12 weeks of telaprevir with 24 weeks of
peg-IFN alfa-2a and RBV, and 48 weeks of peg-
IFN alfa-2a and RBV (control group). AEs (tela-
previr group vs control group) included fatigue
(54% vs 46%), rash (54% vs 32%), nausea (51% vs
32%), flu-like symptoms (47% vs 44%), headache
(41% vs 50%), and pruritus (24% vs 48%). The
incidence of severe rash was 8% in the pooled
telaprevir arm versus 1% in the pooled control
arm. The incidence of anemia was 32% in the tela-
previr arm versus 22% in the control arm.[45]
In these trials, the most common AEs reported
more frequently in the telaprevir treatment arms,
compared with the placebo arms, were gastro-
intestinal events, skin events (rash, pruritus), and
anemia. Other AEs reported were similar in type
and frequency to those seen with currently ap-
proved peg-IFN plus RBV treatment. The most
common AE leading to discontinuation in the
telaprevir arms was rash in approximately 7% of
patients across both PROVE 1 and PROVE 2.
Investigators have reported that rash AEs were
reversible upon discontinuation of treatment,
and a rash management plan was implemented as
part of subsequent telaprevir clinical trials, in-
cluding ongoing phase III trials.[14]
PROVE 3
Interim results showed that skin and gastro-
intestinal disorders were more common in
patients receiving telaprevir-based therapy than
standard therapy alone (peg-IFN-alfa plus RBV;
PR) in the PROVE 3 trial in patients with geno-
type 1 hepatitis C who did not achieve SVR with
prior standard therapy. In the double-blind trial,
453 such patients were randomized to treatment
with the following four regimens: (i) peg-IFN
alfa-2a 180 mg/day once weekly plus RBV
1000–1200mg/day for 48 weeks (control); (ii) tela-
previr 750mg three times daily in combination
with peg-IFN alfa-2a plus RBV for 12 weeks,
followed by 12 weeks of peg-IFN alfa-2a plus
RBV alone; (iii) telaprevir 750mg three times
daily in combination with peg-IFN alfa-2a plus
RBV for 24 weeks, followed by 24 weeks of peg-
IFN alfa-2a plus RBV alone; and (iv) telaprevir
750mg three times daily plus peg-IFN alfa-2a for
24 weeks. The percentages of patients who dis-
continued treatment due to AEs were 4%, 11%,
26%, and 9% in the respective treatment groups.[65]
In final results, AEs occurring with a greater
incidence in the 12-week telaprevir/24-week peg-
IFN-alfa plus RBV or 24-week telaprevir/48-week
peg-IFN-alfa plus RBV arms than the control arm
included fatigue, nausea, headache, rash, pruri-
tus, diarrhea, anemia, insomnia, pyrexia, alo-
pecia, and chills. Grade 3 rash was observed in
5%, 4%, 3%, and 0% of patients in the 12-week
telaprevir/24-week peg-IFN-alfa plus RBV arm,
24-week telaprevir/48-week peg-IFN-alfa plus
RBV arm, 24-week telaprevir/peg-IFN-alfa arm,
and control arm, respectively. Grade 3 anemia
was observed in 0%, 6%, 1%, and 1% of patients
in these groups, respectively.[39]
Phase I : A phase I study showed that combi-
nation therapy with tenofovir disoproxil fuma-
rate (TDF) plus telaprevir and monotherapy with
either drug were generally well tolerated. AEs were
grade 1 or 2. In the study, 18 healthy volunteers
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received TDF 300mg once-daily monotherapy,
telaprevir 750mg every-8-hours monotherapy,
and a combination of both drugs in three sepa-
rate 7-day treatment periods. Two subjects dis-
continued the study: one withdrew consent, the
other due to a non drug-related AE.[66]
2.3 Drug Interactions
TDF did not influence the pharmacokinetic
properties of telaprevir in a phase I study of te-
laprevir in 18 healthy volunteers. Exposure to TDF
however, was increased by about 30% during co-
administration with telaprevir. The least squares
mean ratio (ratio of TDF plus telaprevir to TDF
alone, 90% CI) for the minimum and maximum
plasma concentrations and AUC24 values of TDF
were 1.41, 1.30, and 1.30, respectively. Similar ob-
servations have been reported during combina-
tion treatments of TDF with antiretroviral drugs.
In the study, the subjects received TDF 300mg
once-daily monotherapy, telaprevir 750mg every-
8-hours monotherapy, and a combination of both
drugs, in three separate 7-day treatment periods.
Sixteen of 18 subjects completed the study.[66]
In a phase I trial in approximately 20 healthy
volunteers, the plasma exposure of VX 222 was
increased when it was administered over 10 days
in combinationwith telaprevir, whereas the plasma
exposure of telaprevir was not affected when ad-
ministered in combination with VX 222. For VX
222, doses of 100mg twice daily and 400mg twice
daily, given in combination with telaprevir, were
expected to result in plasma exposures similar to
those noted in previous studies with doses of
250mg twice daily and 750mg twice daily, re-
spectively, when administered as monotherapy in
patients with hepatitis C.[23]
2.4 Antimicrobial Activity
2.4.1 Viral Infections
Analysis of clinical isolates from patients with
HCV genotype 1 infection who were treated with
a combination of telaprevir, peg-IFN alfa-2b and
RBV and experienced disease breakthrough
during therapy or post-treatment relapse showed
complex mixtures of viral variants bearing amino
acid substitutions conferring resistance to tela-
previr. In addition, the amino acid substitutions
appeared to confer improved fitness to telaprevir-
resistant variants.[67]
Dominant mutation(s) selected in the labora-
tory against telaprevir remained sensitive to cilu-
previr, a protease inhibitor which has shown
antiviral activity in HCV patients, and ciluprevir
resistant mutants remained sensitive to telapre-
vir. Analysis of minor mutations that were cross-
resistant to telaprevir and ciluprevir in the
laboratory, and showed that enzymatic activity
of the cross-resistant HCV protease was reduced
approximately 4- to 7-fold, a condition that could
impair the ability of the virus to grow.[68]
Telaprevir exhibits potent and sustained anti-
viral activity in vitro. In these studies, HCV
replicon cells, which mimic the intracellular rep-
lication of HCV, were treated with telaprevir and
were evaluated at multiple timepoints. In one
experiment, treatment with telaprevir for 9 days
reduced HCVRNA by almost 10000-fold (4 log10).
In another experiment, HCV replicon cells treat-
ed with telaprevir for 13 days exhibited viral
clearance at day 13, and no rebound of HCV viral
RNA was observed at day 27.[69]
In vitro, telaprevir inhibited HCV RNA repli-
cation in a time- and dose-dependent fashion. In
a 2-day HCV replicon assay, telaprevir showed a
50% inhibitory dose of 0.35 mmol/L and a 50%
cytotoxicity dose of 83 mmol/L. Various combi-
nations of telaprevir, merimepodib, and IFN-a
often led to synergistic effects or at least additive
effects in reducing HCV RNA. Conditions were
also identified where telaprevir alone or in com-
bination with IFN-a was able to completely clear
HCV RNA, with no rebound effect observed
after withdrawal of the drug.[70]
2.5 Pharmacodynamics
2.5.1 Viral Infections
A novel preclinical HCV protease expression
model was used to stringently evaluate the ability
of telaprevir to inhibit HCV protease in liver
tissue. Telaprevir dosed orally resulted in a sig-
nificant, dose-dependent inhibition of an HCV-
protease enzyme-dependent signal. In untreated
control models, high concentrations of active
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HCV protease enzyme over 7 days were associ-
ated with significant liver damage. However, treat-
ment with telaprevir for the initial 3 days of the
experiment resulted in sharply reduced liver
damage.[69]
A decrease in steatosis was observed in mice
expressing wild type HCV protease after treat-
ment with VX 950.[71]
Results from a clinical study in 34 patients
with genotype 1 HCV infection showed that te-
laprevir (450–1250mg) dose-dependently inhibited
viral production with the median antiviral efficacy




Phase II : Preliminary results from a phase II
trial demonstrated that at the end of week 2,
plasma HCV RNA was <30 IU/mL in 11 of 12
patients and <10 IU/mL in 3 of 12 patients and at
the end of week 3, levels were <30 IU/mL in 12 of
12 and <10 IU/mL in 9 of 12. At the end of the
28 day trial, 12 of 12 patients had levels <10 IU/mL.
No patients demonstrated evidence of viral break-
through while receiving treatment.[54]
Phase I :Results from a double-blind, placebo-
controlled, phase Ib trial demonstrated that
treatment with oral suspension telaprevir resulted
in significantly reduced plasmaHCVRNA levels.
In the trial, 34 patients with chronic genotype 1
HCV infection were randomized to receive telap-
revir 450mg every 8 hours, 1250mg every 12 hours,
750mg every 8 hours, or placebo over a period of
14 days. After 2 days of treatment, the 26 of 28 pa-
tients who completed the trial, achieved an HCV
RNA reduction of >3 log10 regardless of dose
level. A further reduction was observed between
days 3 and 14 in the group receiving 750mg every
8 hours, with mean reductions of 4.4 log10 at day
14. The highest trough plasma concentrations
were observed in the 750mg every 8 hour group.
In the other dose groups, maximal effects were
observed between 3 and 7 days of treatment, after
this an increase in median HCV RNA levels of
approximately 1 log10 between days 7 and 14 was
observed in both of these groups. At the end of
dosing, five patients across all dose groups tested
HCV RNA negative in the quantitative Roche
COBAS TaqMan assay (<30 IU/mL). Twenty-
eight days after treatment completion, two patients
had viral levels of >1 log10 below pretreatment
levels.[55,57,72]
In a 14-day study, treatment with telaprevir
resulted in a median serum ALT level decline of
25–32U/L in all dose groups, compared with an
8U/L increase in the placebo group. Following
telaprevir treatment, 83% of patients who had
elevated ALT levels at baseline achieved nor-
malization of ALT levels by day 14, compared
with none of the patients in the placebo group.
Treatment with telaprevir also reduced mean se-
rum levels of neopterin.[73]
The rate of SVR may be increased in patients
with chronic genotype 1 hepatitis C who receive a
telaprevir-based regimen, compared with con-
ventional regimens, according to final results of a
phase I trial (VX04-950-103). SVR was attained
in 9 of 15 such patients who were treated with
telaprevir alone or telaprevir plus peg-IFN alfa-
2a for 14 days, followed by peg-IFN alfa-2a plus
RBV for 24 or 48 weeks in total. In contrast, SVR
was achieved in 1 of 4 patients who received peg-
IFN alfa-2a alone over 2 weeks, followed by 48
weeks of peg-IFN alfa-2a plus RBV. At week 12,
HCV DNA could not be detected in all eight
patients in the telaprevir plus peg-IFN alfa-2a
group and five of seven patients who received
telaprevir alone. At week 24, HCVwas not detect-
able in all 15 recipients of telaprevir. Telaprevir
750mg was administered orally as tablets, three
times daily; peg-IFN alfa-2a was administered
once weekly.[74,75]
2.6.2 Combination Therapy
Phase III : Extending telaprevir therapy to
48 weeks did not provide additional benefit over
24weeks of therapy in treatment-naive patientswith
hepatitis C who had achieved a virologic response
at 4 and 12 weeks in the phase III ILLUMINATE
study. In this study, approximately 500 patients
who had undetectable HCV levels at weeks 4 and
12 of treatment with telaprevir in combination
with peg-IFN alfa-2a and RBV were randomized
to receive either 24 or 48 weeks of additional
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therapy. The SVR rates were 92% and 88% in the
24- and 48-week treatment groups, respectively.
Relapse rates were 5.7% and 1.9%, respectively.[24]
A total of 75% of patients with chronic geno-
type 1 HCV infections achieved a SVR after 12
weeks of treatment with a telaprevir-based com-
bination regimen, in the phase III ADVANCE
trial. In this double-blind study, patients
(n= 1095) were randomized to receive either telap-
revir for 8 or 12 weeks, in combination with peg-
IFN and RBV, or peg-IFN and RBV alone.
Following the completion of the telaprevir treat-
ment phase, patients in the 12-week telaprevir
arm received peg-IFN and RBV for a subsequent
12 or 36 weeks, based on response to treatment at
weeks 4 and 12; and patients in the 8-week tela-
previr arm, received peg-IFN and RBV for a
subsequent 16 or 40 weeks, based on response to
treatment at weeks 4 and 12. Patients in the con-
trol arm received a total of 48 weeks treatment
with peg-IFN and RBV. The SVR rates observed
were 75%, 69%, and 44% for the telaprevir
12-week, telaprevir 8-week and control arms, re-
spectively (p < 0.0001 for both telaprevir arms
compared with control). A total of 68%, 66%,
and 9% of patients in each of the respective
treatment arms, had undetectable HCV RNA
levels 4 weeks after the initiation of treatment
(defined as rapid viral response; RVR). Further-
more, viral relapse (defined as the proportion of
patients who achieved undetectable HCV RNA
at the completion of treatment but relapsed dur-
ing post-treatment follow-up) was observed in
8.6%, 9.5%, and 28% of the telaprevir 12-week, 8-
week and control arms, respectively.[16]
Phase II : Preliminary results of a proof-of-
concept, phase IIa (C210; NCT00580801) study
indicated that telaprevir plus peg-IFN alfa-2a
plus RBV showed greater antiviral activity than
telaprevir monotherapy or peg-IFN alfa-2a plus
RBV alone in treatment-naive patients with
hepatitis C genotype 4.[76,77]
Among hepatitis C genotype 2 and genotype 3
subjects receiving telaprevir monotherapy in a
phase IIa study, six and three patients, respect-
ively, developed a viral breakthrough by day 15;
no viral breakthroughs were observed in the
TPR2&PR22 arm. Viral breakthroughs were
associated with viral variants with decreased
susceptibility to telaprevir. Three genotype 2 and
one genotype 3 patients with viral breakthroughs
who continued treatment with peg-IFN plus RBV
achieved a SVR. SVR rates in genotype 2/3-infected
subjects were 56%/50%, 100%/67%, and 89%/44%
for arms A, B, and C, respectively. Among gen-
otype 2/genotype 3 subjects receiving telaprevir
monotherapy, six of nine and three of eight pa-
tients, respectively, developed a viral breakthrough
by day 15; no viral breakthroughs were observed
in arm B. The trial enrolled subjects with geno-
type 2/3 hepatitis Cwhowere randomized to receive
15 days of telaprevir (750mg every 8 hours) followed
by peg-IFN (180mg/week) and RBV (800mg/day)
for 24 weeks (T2&PR24), telaprevir and peg-IFN
plus RBV followed by 22 weeks of peg-IFN plus
RBV (TPR2&PR22), or placebo and peg-IFN
plus RBV followed by 22 weeks of peg-IFN plus
RBV (Pbo/PR24).[59,77-79]
Analysis of the natural prevalence of hepatitis
C variants in patients prior to combination treat-
ment in two phase II trials, revealed that treat-
ment with telaprevir plus peg-IFN alfa-2a plus
RBV is effective against the V36M and R109K
variants.[80]
When administered with peg-IFN plus RBV,
telaprevir appeared to have considerable activity
against genotype 1 hepatitis C, based on the 4-
week interim analysis of Study C208. In this non-
blind, phase II trial, 161 treatment-naive patients
were randomized to receive one of four different
regimens (arms A-D) combining telaprevir, ad-
ministered 8-hourly or 12-hourly, with peg-IFN
alfa-2a or peg-IFN alfa-2b, plus RBV, for 12
weeks. The numbers of patients were 40, 42, 40,
and 39 in arms A, B, C, and D, respectively. Te-
laprevir was administered as 750mg every 8 hours
(arms A and B) or as 1125mg every 12 hours
(arms C and D). Patients received peg-IFN alfa-
2a 180 mg/week and RBV 1000–1200mg/day in
arms A and C, and peg-IFN alfa-2b 1.5mg/kg/week
and RBV 800–1200mg/day in arms B and D. The
proportions of patients achieving undetectable
HCV RNA at week 4 were greater for study arms
A and C (82% and 85%, respectively) than for
arms B and D (71% and 68%, respectively); the
differences in HCVRNA clearance between arms
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A and C, and arms B and D were not statistically
significant. Viral breakthrough was reported in,
at most, two patients in any study arm, and dis-
continuation rates were similar in all arms.[18,81,82]
According to the ITT analysis data, SVR rates in
the study C208 were 82% and 83% in patients re-
ceiving 12-hourly telaprevir-based regimen (peg-
IFN plus RBV), respectively, and 81% and 85%
in patients in an 8-hourly telaprevir-based regimen,
respectively. The majority of patients achieved
these SVR rates within a 24-week telaprevir-based
regimen.[26,27]
Results of a non-blind study indicated that
patients with genotype 1 hepatitis C who do not
respond to peg-IFN alfa-2a plus RBV can ach-
ieve treatment response with a regimen based on
telaprevir. Patients who did not achieve SVR in
the peg-IFN alfa-2a plus RBV control arms of
the PROVE studies received telaprevir 750mg
every 8 hours and peg-IFN alfa-2a plus RBV at
standard doses for 12 weeks, followed by peg-
IFN alfa-2a plus RBV for 12 weeks (relapsers or
partial responders in PROVE) or 36 weeks (null
responders in PROVE). Seventy-two patients re-
ceived at least one dose of the study drugs; 60, 36,
and 16 patients had been treated for 4, 8, and 12
weeks, respectively. In PROVE, null responders
were defined by a decrease in HCV RNA of
<1 log10 at week 4 or <2 log10 at week 12, partial
responders by ‡2 log10 decrease in HCV RNA at
week 12 and detectable HCV RNA at week 24,
and relapsers by an end-of-treatment response
but with relapse after 48 weeks of treatment with
peg-IFN alfa-2a plus RBV.
Final results showed that 51% and 53% of
patients achieved a SVR after treatment with te-
laprevir as part of 24- and 48-week regimens,
respectively. The SVR rate in the control group
was 14%.[83] Previous interim data showed that,
in the non-blind study at week 4, HCV RNA was
<10 IU/mL in 8 of 24 null responders (week 4),
five of ten null responders (week 12), 15 of 19
partial responders and four of five relapsers. At
week 12, HCV RNA was <10 IU/mL in eight of
nine null responders (week 4), three of three null
responders (week 12), one of one partial res-
ponders and two of two relapsers. Two pa-
tients (both null responders at week 4 in PROVE)
experienced viral breakthrough (>1 log10 increase
above the nadir of HCV RNA, or >100 IU/mL
HCVRNA) at week 2.[34,35,84] Additional interim
data from 104 enrolled patients showed that a high
proportion of treatment-failure patients with
HCV genotype 1 infection had a rapid viral res-
ponse to treatment with telaprevir. These patients
maintained undetectable levels of HCV RNA
(<10 IU/mL) through 24 weeks of treatment.[18]
Telaprevir in combination with peg-IFN alfa-2a
plus RBV has strong antiviral activity in patients
with hepatitis C, according to results from a
phase II study (VX05-950-102). Twelve treat-
ment-naive patients with genotype 1 hepatitis C
received 750mg of oral telaprevir every 8 hours
plus standard schedules of peg-IFN alfa-2a plus
RBV, for 28 days. After completing this regimen,
all patients received follow-on peg-IFN alfa-
2a plus RBV treatment. At 28 days, all 12 pa-
tients had undetectable plasma HCV RNA levels
(<10 IU/mL), and no patients showed evidence of
viral breakthrough while receiving telaprevir. At
week 12 of the follow-on therapy, 11 patients still
had undetectable hepatitis C viral RNA levels.
Final results showed that SVR was achieved in
seven of seven patients who completed 48 weeks
of treatment. Two patients had viral break-
throughs after 12 and 24 weeks of treatment. Two
patients who were lost to follow-up had undetect-
able plasma HCV when last assessed; overall,
eight of ten patients for whom results were avail-
able attained SVR.[30,60]
Data from a phase II rollover study (VX06-
950-107 or Study 107; NCT00535847) have
shown that 59% of patients overall who received
telaprevir-based combination therapy achieved
SVR after failing to achieve SVRwith at least one
prior course of HCV therapy. Specifically, 56% of
null-responders to prior therapy (n = 27) achieved
SVR after treatment with a 48-week telaprevir-
based combination regimen, and 97% of prior
treatment relapsers (n= 29) and 55% of prior treat-
ment partial responders (n= 29) achieved SVR after
treatment with a 24-week or 48-week telaprevir-
based combination regimen. The overall relapse
rate in this study was 16%. Study 107 was an
open-label study of patients who did not achieve
SVR after receiving peg-IFN alfa-2a plus RBV in
Telaprevir 191
ª 2010 Adis Data Information BV. All rights reserved. Drugs R D 2010; 10 (3)
the control arms of the phase II PROVE trials
(PROVE 1, PROVE 2, or PROVE 3) of telaprevir.
Patients in Study 107 were characterized as null
responders, partial responders, relapsers, or break-
throughs, based on their antiviral response docu-
mented as a result of their participation in the
control arms of the PROVE trials. A total of
117 patients enrolled in Study 107, including
51 patients with prior treatment null response,
29 patients with prior treatment partial response,
eight patients with prior treatment viral break-
through, and 29 patients with prior treatment
relapse. When Study 107 first began, all patients
were to receive 12 weeks of telaprevir in combi-
nation with peg-IFN plus RBV followed by an
additional 12 weeks of peg-IFN plus RBV, for a
total of 24 weeks of therapy. In 2008, Study 107
was amended and underwent several changes,
most notably to the duration of treatment. Fol-
lowing these amendments, only patients who did
not achieve HCV RNA £100 IU/mL at week 4
were required to stop therapy. In addition, prior
treatment null responder patients were to receive
a 48-week telaprevir-based treatment regimen.
Patients with prior treatment relapse, prior
treatment viral breakthrough and prior treat-
ment partial response were eligible to receive a
response-guided, 24-week telaprevir-based treat-
ment regimen if they achieved undetectable HCV
RNA at week 4 and 12, otherwise these patients
would receive a 48-week regimen.[36,37] These re-
sults were consistent with interim data reported
from 94 of total 117 patients enrolled in Study
107.[38] Results released at EASL 2010 for Study
107 show viral breakthrough and relapse rates
occurred in 25%, 23% of prior null responders;
10%, 22% of prior partial responders; 13%, 0% of
prior viral breakthroughs; and 0%, 4% of prior
relapsers.[61]
2.6.3 PROVE (Phase IIb) Trials
PROVE 1
Final data from the PROVE 1 trial (VX05-
950-104) have shown that telaprevir significantly
improved the proportion of treatment-naive
patients who were cured of their HCV genotype 1
infection, and also shortened the duration of
HCV therapy from 48 to 24 weeks for the ma-
jority of patients. The primary endpoint of the
PROVE 1 was the proportion of patients who
had undetectable plasma HCV RNA 24 weeks
after the completion of therapy (i.e. SVR).
PROVE 1 was a phase IIb, randomized, double-
blind, placebo-controlled trial that enrolled and
treated 250 treatment-naive patients with HCV
genotype 1 infection at 37 clinical trial sites in
the US. Patients received telaprevir 750mg (or
placebo) orally every 8 hours, based on treatment
arm, and a once-weekly 180 mg injection of peg-
IFN alfa-2a, as well as a 1000mg or 1200mg
weight-based daily oral dose of RBV. PROVE 1
consisted of the following four treatment arms:
(i) a 24-week telaprevir-based arm consisting of
12 weeks of telaprevir in combination with peg-
IFN and RBV, followed by an additional 12 weeks
of peg-IFN and RBV alone; (ii) a 48-week telap-
revir-based arm consisting of 12 weeks of telap-
revir in combination with peg-IFN and RBV,
followed by an additional 36 weeks of peg-IFN
and RBV alone; (iii) a 12-week telaprevir-based
arm consisting of 12 weeks of telaprevir in com-
bination with peg-IFN and RBV; and (iv) a
control arm consisting of 12 weeks of placebo in
combination with peg-IFN and RBV, followed
by 36 weeks of peg-IFN and RBV alone. Patients
who received the 24-week telaprevir-based regi-
men (arm 1) versus control regimen had a SVR
rate of 61% versus 41%, an RVR rate of 81% vs
11%, and a relapse rate of 2% versus 23%. The
relapse rate in treatment arm 1 reflected only those
patients who achieved an RVR and remained
undetectable through week 20. Of the small sub-
group of African American patients enrolled in
PROVE 1, SVR was achieved by 44% of patients
in the telaprevir arms versus 11% in the control
group. SVR rates in African Americans are typi-
cally lower than in other ethnic groups. African
Americans are also disproportionately infected with
HCV, compared with other ethnic groups.[14,46]
These final data were consistent with earlier
reported interim results, which showed that 88%
of patients receiving telaprevir plus peg-IFN alfa-
2a plus RBV had an undetectable level of HCV
RNA (<10 IU/mL). Fifty-five percent of patients
who received placebo plus peg-IFN alfa-2a plus
RBV demonstrated an undetectable level of HCV
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RNA. Six of nine patients treated with telaprevir
continued to have undetectable HCV RNA levels
20 weeks after stopping treatment. In addition,
nine patients stopped treatment after 12 weeks
after achieving a RVR (<10 IU/mL) at week 4 and
maintenance of this viral response at week 10 of
treatment. Of these patients, six continued to
have an undetectable HCVRNA at week 20.[43,63]
Further interim PROVE 1 data showed that 79%
of 182 patients with genotype 1 hepatitis C who
received telaprevir plus peg-IFN alfa-2a plus
RBV had non-detectable HCV RNA at week 4
(RVR), compared with 11% of 81 patients who
received only peg-IFN alfa-2a plus RBV (p< 0.001).
At week 12, the respective percentages were 70%
and 39% (p < 0.001). Viral breakthroughs in the
first 12 weeks of treatment were noted in 12 of
175 patients who received telaprevir plus peg-
IFN alfa-2a and RBV. Of nine patients with a
RVR who received a further 12 weeks treatment
with peg-IFN alfa-2a plus RBV, six achieved
SVR; the other three relapsed with telaprevir-
resistant variants of HCV.[62] After 48 weeks, the
percentage of patients with non-detectable HCV
RNA was respectively 65% and 45% in recipients
of 12 weeks’ treatment with telaprevir, peg-IFN
alfa-2a plus RBV followed by 36 weeks’ treat-
ment with peg-IFN alfa-2a plus RBV and a con-
trol group that received 48 weeks’ treatment with
peg-IFN alfa-2a plus RBV only.[85]
PROVE 2
Final results from the PROVE 2 study con-
firmed final data from the PROVE 1 trial – that
telaprevir significantly improved the proportion
of treatment-naive patients who were cured of
HCV genotype 1 infection, and also shortened
the duration of HCV therapy from 48 to 24 weeks
for the majority of patients. PROVE 2 was an-
other phase IIb, randomized, partially double-
blind, placebo-controlled trial that enrolled and
treated 323 treatment-naive patients with HCV
genotype 1 infection at 28 clinical trial sites in
France, Germany, the UK, and Austria. As in
PROVE 1, patients in PROVE 2 received telap-
revir 1250mg as a single dose on day 1 and then
750mg (or placebo) orally every 8 hours, based
on treatment arm, a once-weekly 180 mg injection
of peg-IFN alfa-2a, as well as a 1000mg or
1200mg weight-based daily oral dose of RBV.
PROVE 2 consisted of the following four treat-
ment arms: (i) a 24-week telaprevir-based arm
consisting of 12 weeks of telaprevir in combina-
tion with peg-IFN and RBV, followed by an ad-
ditional 12 weeks of peg-IFN and RBV alone;
(ii) a 12-week telaprevir-based arm consisting of
12 weeks of telaprevir in combination with peg-
IFN and RBV; (iii) a 12-week telaprevir-based
arm consisting of 12 weeks of telaprevir in com-
bination with peg-IFN (no RBV); and (iv) a con-
trol arm consisting of 12 weeks of placebo in
combination with peg-IFN and RBV, followed
by 36 weeks of peg-IFN and RBV alone. Patients
who received the 24-week telaprevir-based regi-
men (arm 1) versus control regimen had a SVR
rate of 69% versus 46%, an RVR rate of 69%
versus 13%, and a relapse rate of 14% versus 22%.
For patients in treatment arm 1 who achieved an
RVR and remained undetectable through week
12, the relapse rate was 7%.[14,18,47,48,64,86]
PROVE 1 and PROVE 2 Pooled Analysis
A pooled subgroup analysis of PROVE 1 and
2 showed that telaprevir-based triple therapy
improved SVR rates in patients predicted to have
low virologic response to current standard treat-
ment. Two identical treatment regimen arms were
pooled: 12 weeks of telaprevir with 24 weeks of
peg-IFN alfa-2a plus RBV, and 48 weeks of peg-
IFN alfa-2a plus RBV (control group). Overall
SVR rates were 65% for the pooled telaprevir arm
and 44% for the pooled control arm (p = 0.0001).
By logistic regression analysis, treatment group,
baseline HCV RNA level, age group, and race
were predictors of SVR.[45]
PROVE 3
Final results from a phase IIb study (PROVE
3) involving 453 patients with HCV genotype 1
infection who failed prior treatment with peg-
IFN plus RBV have shown that SVR rates in all
treatment groups who received telaprevir-based
therapy were significantly higher than those who
received peg-IFN alfa-2a plus RBV. In this study,
telaprevir was given at a single oral dose of
1250mg for the first dose followed by a 750mg
dose every 8 hours for the predefined treatment
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period. peg-IFN alfa-2a was administered at
180mg each week by subcutaneous injection. RBV
was administered twice daily at 1000mg/day for
patients weighing <75 kg and 1200mg/day for
patients weighing ‡75 kg. Patients received either
telaprevir plus peg-IFN alfa-2a plus RBV for 12
weeks followed by placebo and peg-IFN alfa-2a
plus RBV for 12 weeks (T12PR24 group; n= 115);
or telaprevir plus peg-IFN alfa-2a plus RBV for
24 weeks followed by peg-IFN alfa-2a plus RBV
for 24 weeks (T24PR48 group; n = 113); or tela-
previr plus peg-IFN alfa-2a for 24 weeks PR48
(T24P24 group; n= 111); or placebo plus peg-
IFN alfa-2a plus RBV for 24 weeks followed by
peg-IFN alfa-2a plus RBV for 24 weeks (control;
n= 114). SVR rates (primary endpoint) were 51%
in the T12PR24 group, 53% in the T24PR48
group, 24% in T24P24 group, versus 14% in
the control group; the differences between the
telaprevir-based regimens versus control were all
statistically significant. Among prior relapsers,
SVR rates were 69% in the T12PR24 group, 76%
in the T24PR48 group, 42% in the T24P24 group,
and 20% in the control group. Among prior non-
responders, SVR rates were 39% in the T12PR24
group, 38% in the T24PR48 group, 11% in the
T24P24 group, and 9% in the control group. Viral
breakthrough rates through week 24 were 13% in
the T12PR24 group, 12% in the T24PR48 group,
32% in the T24P24 group, and 3% in the PR48
group. In all telaprevir-based treatment groups,
the majority of patients with viral breakthrough
were prior nonresponders. All patients who re-
ceived telaprevir and achieved virologic response
maintained it for 48 weeks after the end of the
treatment. Adding telaprevir to the treatment regi-
men resulted in cure of approximately 50% of this
patient population who have failed therapy and
for which no other options currently exist.[40,87-89]
The above results were consistent with pre-
viously reported results. An ITT analysis of a
phase IIb study (PROVE 3; study VX06-950-106)
showed that telaprevir-based regimen produced
superior SVR, compared with peg-IFN alfa-2a
plus RBV alone, in patients with genotype 1
hepatitis C who did not achieve SVR with prior
peg-IFN alfa-2a plus RBV therapy; 51% and 52%
of patients achieved SVR in the 24- and 48-week
telaprevir-based regimens, respectively, compared
with 14% in 48-week peg-IFN alfa-2a plus RBV
therapy (control); 69% and 76% of prior relapsers
in the 24- and 48-week telaprevir arm, respect-
ively, achieved SVR as compared with 20% in
control; 39% and 38% of prior nonresponders in
the 24- and 48-week telaprevir arms, respectively,
achieved SVR as compared to 9% in the control.
A sub-analysis showed that 53% and 45%, re-
spectively, of patients with cirrhosis in the 24- and
48-week telaprevir arms achieved SVR compared
with 8% in the control arm. An overall response
rate was observed in 10 of 76 and 26 of 87 patients
in 48- and 24-week telaprevir arm, respectively.
The relapse rates were 2 of 53 and 22 of 80 pa-
tients who completed 48- and 24-week telaprevir
treatment respectively, compared with 17 of 33 in
control.[41,90]
Viral breakthrough rates were 11%, 10%, 21%,
and 3% in the 12-week telaprevir/24-week peg-
IFN alfa-2a plus RBV arm, 24-week telaprevir/
48-week peg-IFN alfa-2a plus RBV arm, 24-week
telaprevir/peg-IFN alfa-2a arm, and control arm,
respectively. Relapse rates were 28%, 4%, 53%,
and 52% in those groups, respectively, 24 weeks
after treatment. No late relapses occurred 48 weeks
after treatment in the telaprevir regimens.[39]
Interim results showed that telaprevir-based
therapy appeared to be effective in the PROVE 3
trial in patients with HCV genotype 1 failed to
achieve SVR with prior peg-IFN alfa-2a plus
RBV therapy. In the double-blind trial, 453 such
patients were randomized to treatment with the
following four regimens: (i) peg-IFN alfa-2a
180mg/dayonceweekly plusRBV1000–1200mg/day
for 48 weeks; telaprevir 750mg three times daily
in combination with peg-IFN alfa-2a plus RBV
for 12 weeks, followed by 12 weeks of peg-IFN
alfa-2a plus RBV alone; telaprevir 750mg three
times daily in combination with peg-IFN alfa-2a
plus RBV for 24 weeks, followed by 24 weeks of
peg-IFN alfa-2a plus RBV alone; and telaprevir
750mg three times daily plus peg-IFN alfa-2a for
24 weeks. Between 41% and 72% of patients ran-
domized to receive treatment with a 24-week te-
laprevir-based regimen maintained undetectable
viral load at 12 weeks post-treatment.[65] Earlier
interim results of PROVE 3 had shown that 60
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Table II. History
Date Comment
13 August 2010 inThought analysis for hepatitis C updated
10 August 2010 Efficacy and adverse events data from the phase III ILLUMINATE trial in hepatitis C released by Vertex
Pharmaceuticals[24]
28 July 2010 Preregistration for hepatitis C (treatment-experienced patients) in the US (PO)
28 July 2010 Preregistration for hepatitis C (treatment-naive patients) in the US (PO)
26 May 2010 Efficacy and adverse event data from the phase III ADVANCE trial in hepatitis C virus infections released by Vertex
Pharmaceuticals[16]
20 April 2010 Efficacy and adverse events data from three phase II trials in hepatitis C presented at the 45th Annual Meeting of the
European Association for the Study of the Liver (EASL-2010)[59,61,78,87]
16 April 2010 Efficacy and adverse events data from a phase II rollover trial (Study 107) in treatment-experienced patients with
hepatitis C presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL-
2010)[36,37]
9 April 2010 Final efficacy data added from the phase IIb trial (PROVE 3) in patients with hepatitis C who have failed prior
therapy[88,89]
6 April 2010 Vertex and Tibotec complete a phase I trial in healthy volunteers to assess effect of telaprevir on pharmacokinetics on
tacrolimus and ciclosporin in the US
26 March 2010 Tibotec completes a phase I trial (NCT00903773) in hepatitis C in Ireland
24 March 2010 Tibotec and Vertex initiate enrollment in a roll-over trial for the REALIZE trial for hepatitis C virus infection in the US,
EU, South America, and Australia.
24 March 2010 Vertex and Tibotec complete a phase II trial (NCT00535847) of telaprevir plus standard therapy in the US, Canada,
and the EU in patients who participated in the control arms of previous studies and did not respond to therapy
17 March 2010 Tibotec and Vertex complete enrollment in a phase I trial in healthy volunteers to evaluate the effects of telaprevir on
the pharmacokinetics of ciclosporin and tacrolimus in the US
2 March 2010 Tibotec completes enrollment in a phase I study in subjects with renal impairment in Ireland
1 March 2010 Drug interactions data from a phase-I trial in healthy volunteers released by Vertex Pharmaceuticals[23]
1 March 2010 Vertex Pharmaceuticals initiates a phase-II trial of combination therapy with VX 222 for hepatitis C in treatment-naive
patients in the US
5 February 2010 All patients in the phase III ADVANCE, ILLUMINATE, and REALIZE trials have completed dosing of all
study drugs[17]
29 January 2010 Tibotec and Vertex initiate enrollment in a phase I trial in healthy volunteers to evaluate the effects of telaprevir on the
pharmacokinetics of ciclosporin and tacrolimus in the US
3 November 2009 Final efficacy and adverse events data from the phase IIb PROVE 3 trial in hepatitis C presented at the 60th Annual
Meeting of the American Association for the Study of Liver Diseases (AASLD-2009)[39,40]
3 November 2009 Pooled efficacy and adverse events data from the phase IIb PROVE 1 and PROVE 2 trials in hepatitis C presented at
the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2009)[45]
31 October 2009 Efficacy, adverse events and pharmacokinetics data from a phase II study (C208) in hepatitis C presented at the 60th
Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2009)[26,27]
30 October 2009 Interim safety and efficacy data from Study 107 in hepatitis C released by Vertex[38]
6 October 2009 Phase II clinical trials in treatment-naive hepatitis C (with HIV co-infection) in the US (PO)
30 July 2009 Mitsubishi Tanabe Pharma and Vertex Pharmaceuticals amend agreement for the development and
commercialization of telaprevir in Asia[7]
10 July 2009 The rights to milestone payments for telaprevir in the EU are available for purchase (http://www.vrtx.com)
31 May 2009 Vertex completes the phase II PROVE 3 trial in hepatitis C in the US, Canada, and the EU, and Tibotec completes a
phase II viral kinetics study in hepatitis C in Europe
29 April 2009 Final efficacy and adverse events data from two phase IIb trials (PROVE 1 and PROVE 2) in treatment-naive patients
with hepatitis C genotype 1 infection released[14,46,47]
26 April 2009 Antimicrobial data from an in vitro study in hepatitis C presented at the 44th Annual Meeting of the European
Association for the Study of the Liver (EASL-2009)[67]
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Table II. Contd
Date Comment
26 April 2009 Interim efficacy data from a phase II, C209 trial in hepatitis C presented at the 44th Annual Meeting of the European
Association for the Study of the Liver (EASL-2009)[77,79]
26 April 2009 Interim efficacy data from a phase IIa, C210 trial in hepatitis C presented at the 44th Annual Meeting of the European
Association for the Study of the Liver (EASL-2009)[76,77]
25 April 2009 Efficacy data from an intent-to-treat analysis of a phase II trial (PROVE 3) in hepatitis C presented at the 44th Annual
Meeting of the European Association for the Study of the Liver (EASL-2009)[41,90]
31 January 2009 Vertex and Tibotec complete enrollment in the phase-III trial ILLUMINATE in hepatitis C in the US, Puerto Rico, and
the EU, and in an open-label phase IIa trial (VX06-950-107) in hepatitis C in the US, Canada, and the EU
15 December 2008 New score for hepatitis C (PO)
20 November 2008 Phase III clinical trials in hepatitis C (treatment-experienced patients) in Australia (PO)
20 November 2008 Phase III clinical trials in hepatitis C (treatment-experienced patients) in Canada (PO)
20 November 2008 Phase III clinical trials in hepatitis C (treatment-experienced patients) in Puerto Rico (PO)
20 November 2008 Tibotec initiates enrollment in the phase III, REALIZE trial for hepatitis C (treatment-experienced patients) in Europe
4 November 2008 Interim efficacy and adverse events data from phase II trials in hepatitis C presented at the 59th Annual Meeting of the
American Association for the Study of Liver Diseases (AASLD-2008)[65,81,82,84]
1 November 2008 Final efficacy and safety data from the phase II, PROVE 2 trial in hepatitis C presented at the 59th Annual Meeting of
the American Association for the Study of Liver Diseases (AASLD-2008)[18,48]
1 November 2008 Interim efficacy data from the PROVE 3, C208 and Study 107, phase II trials in hepatitis C presented by Vertex at the
59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2008)[18]
31 October 2008 Vertex and Tibotec complete enrollment in the phase III ADVANCE trial for hepatitis C in treatment-naive patients
30 October 2008 Phase III clinical trials in treatment-naive and treatment-experienced patients with hepatitis C in Japan (PO)
28 October 2008 Drug interactions and adverse events data from a phase I trial in healthy volunteers presented at the 48th Annual
Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious
Diseases Society of America (ICAAC/IDSA-2008)[66]
17 October 2008 Tibotec initiates enrollment in the phase III, REALIZE trial for hepatitis C (treatment-experienced patients) in the US
30 September 2008 Vertex and Tibotec initiate a phase III trial, ILLUMINATE, for hepatitis C in the US, Belgium, the Netherlands, and
Puerto Rico
19 August 2008 Phase III clinical trials in hepatitis C (treatment-experienced patients) in the EU (PO)
19 August 2008 Phase III clinical trials in hepatitis C (treatment-experienced patients) in the US (PO)
30 June 2008 Phase III clinical trials in hepatitis C (treatment-naive patients) in the EU (PO)
9 June 2008 Interim efficacy data from a phase IIb (PROVE 3) trial in HCV patients who have failed prior treatment released by
Vertex[42]
27 April 2008 Efficacy data from three clinical trials presented at the 43rd Annual Meeting of the European Association for the Study
of the Liver (EASL-2008)[34,35,80,91]
14 March 2008 Phase III clinical trials in hepatitis C (treatment-naive patients) in Puerto Rico (PO)
14 March 2008 Phase III clinical trials in hepatitis C (treatment-naive patients) in the US (PO)
14 March 2008 Vertex Pharmaceuticals and Tibotec initiate patient recruitment in the ADVANCE study in treatment-naive patients
with hepatitis C genotype 1 infection in the US and Puerto Rico
31 December 2007 Phase II clinical trials in hepatitis C in Japan (PO)
9 November 2007 Tibotec initiates enrollment in a phase II trial for hepatitis C treatment in Europe
6 November 2007 Efficacy data and adverse event data from phase II trials (including PROVE 1 and PROVE 2) in hepatitis C presented
at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2007)[60,62,64,74,85,86]
1 October 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
12 June 2007 Vertex completes enrollment in the PROVE 3 trial for hepatitis C in the US, Canada, and the EU
15 April 2007 Interim efficacy data from a phase II trial in hepatitis C released by Vertex Pharmaceuticals[63]
5 February 2007 Vertex initiates enrollment in the PROVE 3 trial for hepatitis C virus in the US, Canada, and the EU
31 January 2007 Phase II clinical trials (PROVE 3) in hepatitis C (treatment-experienced patients) in Germany (PO)
Continued next page
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31 January 2007 Phase II clinical trials (PROVE 3) in hepatitis C (treatment-experienced patients) in Netherlands (PO)
31 January 2007 Phase II clinical trials (PROVE 3) in hepatitis C (treatment-experienced patients) in Puerto Rico (PO)
31 January 2007 Phase II clinical trials (PROVE 3) in hepatitis C (treatment-experienced patients) in the US (PO)
31 January 2007 Phase II clinical trials (PROVE 3) in hepatitis C (treatment-experienced) in Canada (PO)
8 January 2007 Vertex Pharmaceuticals completes enrollment in the PROVE 2 trial in Europe for hepatitis C
15 December 2006 Interim results from a phase II clinical trial (PROVE 1) in patients with hepatitis C infection added to the adverse
events and viral Infections therapeutic trials sections[43]
27 July 2006 Phase I clinical trials in hepatitis C treatment in Asia (PO)
5 July 2006 Telaprevir has been licensed to Janssen. Vertex retains the rights for North America
29 May 2006 Vertex has initiated enrollment in a phase II trial for hepatitis C in the US and Europe
24 May 2006 Data presented at the Digestive Disease Week 2006 conference (DDW-2006) have been added to the adverse
events and viral infections therapeutic trials sections[30]
23 May 2006 Phase II clinical trials in hepatitis C treatment in Europe (PO)
10 February 2006 Data from a media release have been added to the adverse events and viral infections therapeutic trials sections[54]
12 December 2005 Data presented at the 56th Annual Meeting and Postgraduate Course of the American Association for the Study of
Liver Diseases (AASLD-2005) have been added to the adverse events, pharmacokinetics and viral infections
pharmacodynamics sections[52,58]
8 December 2005 Telaprevir has received fast track status for hepatitis C virus infection in the US (PO, tablet)
7 December 2005 Phase II clinical trials in hepatitis C treatment in the US (PO)
21 November 2005 Data from a media release have been added to the viral infections therapeutic trials section[73]
15 November 2005 Vertex has filed an IND with the US FDA for hepatitis C
11 November 2005 Vertex has initiated enrollment in a phase Ib combination trial for hepatitis C in Europe
7 June 2005 Data presented at the Digestive Disease Week and the 106th Annual Meeting of the Gastroenterological Association
(DDW-2005) have been added to the adverse events section[56]
12 May 2005 Data from amedia release have been added to the adverse events and viral infections therapeutic trials sections[55,57]
11 November 2004 Phase-Ib clinical trials in hepatitis C treatment in Europe (PO)
8 November 2004 Additional phase Ia data have been added to the adverse events and pharmacokinetics section[49]
3 November 2004 Data presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-
2004) have been added to the adverse events, pharmacokinetics and viral infections pharmacodynamics
sections[51,71]
30 September 2004 Vertex has completed a phase Ia trial in hepatitis C treatment in Europe
10 September 2004 Clinical data from a media release have been added to the adverse events and pharmacokinetics sections[50]
9 September 2004 Vertex has completed patient dosing a phase Ia trial in healthy volunteers in Europe
18 June 2004 Telaprevir has been licensed to Mitsubishi Pharma in Japan and Far East countries
11 June 2004 Phase I clinical trials in hepatitis C treatment in Europe (PO)
1 June 2004 Data presented at the 17th International Conference on Antiviral Research (ICAR-2004) have been added to the viral
infections antimicrobial activity section[70]
22 April 2004 Preclinical data from a media release have been added to the viral infections antimicrobial activity section[68]
7 April 2004 Vertex is seeking collaborations to support development and commercialization of telaprevir outside of North America
5 November 2003 Data presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-
2003) have been added to the pharmacodynamics and viral infections antimicrobial activity section[69]
9 January 2003 Vertex will lead development and commercialization of telaprevir
14 January 2002 Vertex has received a $US5 million milestone payment from Lilly for the selection of a lead drug candidate for the
treatment of hepatitis C virus infection
10 July 2001 This program is still in active development
6 October 2000 Vertex has received a US patent covering assay technology to accelerate drug discover targeting hepatitis C protease
8 December 1998 New profile
8 December 1998 Preclinical development for hepatitis C in the US (unspecified route)
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of 115 (52%) patients treated with a 24-week
telaprevir-based regimen (12 weeks of telaprevir
with peg-IFN alfa-2a plus RBV followed by 12
weeks of peg-IFN alfa-2a plus RBV alone)
maintained undetectable HCV RNA 12 weeks
post-treatment. Of these 60 patients, 27 (of 66)
were prior non-responders to peg-IFN and RBV,
29 (of 40) were prior relapsers, and 4 (of 9) were
prior breakthroughs.[42]
Pooled Analyses (PROVE Trials)
Interim pooled data from the phase II trials
PROVE 1 and PROVE 2 demonstrated that a
rapid viral response was observed after 4 weeks in
77% of patients with genotype 1HCVwho received
telaprevir, peg-IFN alfa-2a plus RBV and in 12%
of those in a control group that received peg-IFN
alfa-2a plus RBV only. Viral breakthroughs dur-
ing the first 12 weeks of treatment were noted in
5% of recipients of telaprevir, peg-IFN alfa-2a
plus RBV; most of these occurred during the first
4 weeks and were associated with low levels of
IFN in blood.[85,91]
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